Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone dextromethorphan with aspirin and clopidogrel in mild non-cardiogenic ischemic stroke
ChiCTR2300069917Phase 4Not yet recruiting
- Sponsor
- Guangxi Medical University
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of edaravone + dextromethorphan in ischemic stroke and transient ischaemic attack (TIA) (2 arms), sponsored by Guangxi Medical University. Primary endpoints: Modified Rankin Scale (mRS) score and 90-day new stroke events. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
edaravone + dextromethorphan
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on ChiCTR2300069917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069917.